Vascular tone in heart failure: the neuroendocrine-therapeutic interface.
作者信息
Cleland J G, Oakley C M
机构信息
Department of Medicine (Clinical Cardiology), Royal Postgraduate Medical School, Hammersmith Hospital, London.
出版信息
Br Heart J. 1991 Oct;66(4):264-7. doi: 10.1136/hrt.66.4.264.
Abstract
摘要
相似文献
1
Vascular tone in heart failure: the neuroendocrine-therapeutic interface.
Br Heart J. 1991 Oct;66(4):264-7. doi: 10.1136/hrt.66.4.264.
2
ABC of heart failure. Management: diuretics, ACE inhibitors, and nitrates.
BMJ. 2000 Feb 12;320(7232):428-31. doi: 10.1136/bmj.320.7232.428.
3
Drugs for chronic heart failure.
Med Lett Drugs Ther. 1993 May 14;35(896):40-2.
4
15 years of heart-failure trials: what have we learned?
Lancet. 1998 Aug;352 Suppl 1:SI29-33. doi: 10.1016/s0140-6736(98)90016-2.
5
[Angiotensin II antagonists: a promising pathway].
Arch Mal Coeur Vaiss. 2000 Jun;Spec No:10-1, 15.
6
Use of 'Xapril' in patients with chronic heart failure. A paradigm or epitaph for our times?
Circulation. 1994 Sep;90(3):1550-1. doi: 10.1161/01.cir.90.3.1550.
7
Heart failure. New treatment options.
Aust Fam Physician. 1996 Jul;25(7):1035, 1038-43.
8
[Circulatory failure in children with left-to-right shunt in the framework of congenital heart defects: pathophysiology and therapeutic results].
Klin Padiatr. 2000 Mar-Apr;212(2):53-9. doi: 10.1055/s-2000-9652.
9
Heart failure treatment with angiotensin-converting enzyme inhibitors in hospitalized Medicare patients in 10 large states. The Large State Peer Review Organization Consortium.
Arch Intern Med. 1997 May 26;157(10):1103-8.
10
Vasodilator therapy for acute heart failure: haemodynamic comparison of hydralazine/isosorbide, alpha-adrenoceptor blockade, and angiotensin-converting enzyme inhibition.
J Cardiovasc Pharmacol. 1992 Aug;20(2):274-81.
引用本文的文献
1
Venous endothelial function in cardiovascular disease.
Biosci Rep. 2022 Nov 30;42(11). doi: 10.1042/BSR20220285.
2
IP3 receptor orchestrates maladaptive vascular responses in heart failure.
J Clin Invest. 2022 Feb 15;132(4). doi: 10.1172/JCI152859.
3
Genetic manipulation of the cardiac mitochondrial phosphate carrier does not affect permeability transition.
J Mol Cell Cardiol. 2014 Jul;72:316-25. doi: 10.1016/j.yjmcc.2014.04.008. Epub 2014 Apr 21.
4
Role of antithrombotic agents in heart failure.
Curr Cardiol Rep. 2012 Jun;14(3):314-25. doi: 10.1007/s11886-012-0266-x.
5
Determinants of the blood pressure response to the first dose of ACE inhibitor in mild to moderate congestive heart failure.
Br J Clin Pharmacol. 1998 Jun;45(6):559-66. doi: 10.1046/j.1365-2125.1998.00728.x.
6
Neuroendocrine activation after myocardial infarction: causes and consequences.
Heart. 1996 Nov;76(3 Suppl 3):53-9. doi: 10.1136/hrt.76.3_suppl_3.53.
7
The role of the renin-angiotensin and natriuretic peptide systems in the pulmonary vasculature.
Br J Clin Pharmacol. 1995 Jul;40(1):11-8. doi: 10.1111/j.1365-2125.1995.tb04528.x.
8
Optimising heart failure pharmacotherapy: the ideal combination.
Br Heart J. 1994 Aug;72(2 Suppl):S73-9. doi: 10.1136/hrt.72.2_suppl.s73.
9
A comparison of the effects of the selective peripheral alpha 1-blocker terazosin with the selective beta 1-blocker atenolol on blood pressure, exercise performance and the lipid profile in mild-to-moderate essential hypertension.
Clin Auton Res. 1992 Dec;2(6):373-81. doi: 10.1007/BF01831394.
本文引用的文献
1
THE CONTROL OF VENTRICULAR FUNCTION IN MAN.
Br Heart J. 1965 Jan;27(1):1-16. doi: 10.1136/hrt.27.1.1.
2
Effects of sublingual administration of nitroglycerin on pulmonary-artery pressure in patients with failure of the left ventricle.
N Engl J Med. 1957 Dec 5;257(23):1114-7. doi: 10.1056/NEJM195712052572304.
3
Circulatory improvement after hydralazine or isosorbide dinitrate administration in patients with heart failure. Effect on metabolic responses to submaximal exercise.
Am J Med. 1981 Oct;71(4):627-33. doi: 10.1016/0002-9343(81)90216-3.
4
Angiotensin-induced myocardial necrosis and renal failure in the rabbit: distribution of lesions and severity in relation to plasma angiotensin II concentration and arterial pressure.
Cardiovasc Res. 1981 Jan;15(1):43-6. doi: 10.1093/cvr/15.1.43.
5
Prazosin and congestive heart failure: short- and long-term therapy.
Am J Med. 1981 Jul;71(1):147-52. doi: 10.1016/0002-9343(81)90282-5.
6
Hydralazine in the long-term treatment of chronic heart failure: lack of difference from placebo.
Am Heart J. 1982 Sep;104(3):587-94. doi: 10.1016/0002-8703(82)90231-9.
7
Renal hemodynamic effects of vasodilation with nifedipine and hydralazine in patients with heart failure.
J Am Coll Cardiol. 1984 Dec;4(6):1261-7. doi: 10.1016/s0735-1097(84)80147-3.
8
Captopril in heart failure. A double blind controlled trial.
Br Heart J. 1984 Nov;52(5):530-5. doi: 10.1136/hrt.52.5.530.
9
Angiotensin II levels, hemodynamics, and sympathoadrenal function after low-dose captopril in heart failure.
Am J Med. 1984 Nov;77(5):880-6. doi: 10.1016/0002-9343(84)90530-8.
10
Improved exercise capacity and differing arterial and venous tolerance during chronic isosorbide dinitrate therapy for congestive heart failure.
Circulation. 1983 Apr;67(4):817-22. doi: 10.1161/01.cir.67.4.817.
Zotero 插件